QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
QQQ   299.62 (+0.20%)
AAPL   119.05 (+2.11%)
MSFT   214.07 (-0.54%)
FB   276.97 (-0.30%)
GOOGL   1,754.40 (-1.83%)
AMZN   3,168.04 (-0.85%)
TSLA   567.60 (-3.10%)
NVDA   536.06 (+1.06%)
BABA   263.36 (-4.75%)
CGC   28.80 (-0.69%)
GE   10.18 (-2.12%)
MU   64.09 (-0.22%)
AMD   92.66 (+6.27%)
T   28.75 (-0.96%)
NIO   50.53 (-6.43%)
F   9.08 (-0.11%)
ACB   11.68 (+11.56%)
NFLX   490.70 (-0.13%)
BA   210.71 (-2.67%)
GILD   60.67 (+1.07%)
DIS   148.01 (+0.60%)
Log in
NASDAQ:KZIA

Kazia Therapeutics Stock Forecast, Price & News

$9.99
-0.19 (-1.87 %)
(As of 11/30/2020 12:00 AM ET)
Add
Compare
Today's Range
$9.70
Now: $9.99▼
$10.47
50-Day Range
$5.61
MA: $7.46▼
$13.47
52-Week Range
$2.47
Now: $9.99▼
$15.85
Volume215,025 shs
Average Volume309,950 shs
Market Capitalization$94.51 million
P/E RatioN/A
Dividend YieldN/A
Beta2.45
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.36 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KZIA
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.kaziatherapeutics.com
Phone61-2-9472-4101
EmployeesN/A

Debt

Debt-to-Equity RatioN/A
Current Ratio2.10
Quick Ratio2.10

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$710,000.00
Price / Sales133.11
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.31 per share
Price / Book7.63

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding Shares9,460,000
Market Cap$94.51 million
Next Earnings DateN/A
OptionableNot Optionable
$9.99
-0.19 (-1.87 %)
(As of 11/30/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KZIA News and Ratings via Email

Sign-up to receive the latest news and ratings for KZIA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kazia Therapeutics (NASDAQ:KZIA) Frequently Asked Questions

How has Kazia Therapeutics' stock price been impacted by Coronavirus?

Kazia Therapeutics' stock was trading at $3.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, KZIA stock has increased by 151.0% and is now trading at $9.99.
View which stocks have been most impacted by COVID-19.

What stocks does MarketBeat like better than Kazia Therapeutics?

Wall Street analysts have given Kazia Therapeutics a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Kazia Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are some of Kazia Therapeutics' key competitors?

Some companies that are related to Kazia Therapeutics include Bicycle Therapeutics (BCYC), DURECT (DRRX), Syros Pharmaceuticals (SYRS), Tricida (TCDA), Athersys (ATHX), ANI Pharmaceuticals (ANIP), XOMA (XOMA), Selecta Biosciences (SELB), Concert Pharmaceuticals (CNCE), TFF Pharmaceuticals (TFFP), CytomX Therapeutics (CTMX), Calithera Biosciences (CALA), Magenta Therapeutics (MGTA), Verastem (VSTM) and BeyondSpring (BYSI).
View all competitors.

What other stocks do shareholders of Kazia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kazia Therapeutics investors own include Fulcrum Therapeutics (FULC), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Idera Pharmaceuticals (IDRA), MEI Pharma (MEIP), Pfizer (PFE), Translate Bio (TBIO), VYNE Therapeutics (VYNE) and Allena Pharmaceuticals (ALNA).

Who are Kazia Therapeutics' key executives?

Kazia Therapeutics' management team includes the following people:
  • Dr. James Garner M.A.I.C.D., M.B.A., B.Sc., M.A., MBA, MBBS, B.Sc (, CEO, MD & Exec. Director (Age 47)
  • Ms. Gabrielle Heaton, Director of Fin. & Admin.
  • Ms. Catherine Jane Hill B.Sc., C.A., ACA, GAICD, BSc (Hons), Company Sec. (Age 60)
  • Kym Robins, Director of Marketing & Communications

What is Kazia Therapeutics' stock symbol?

Kazia Therapeutics trades on the NASDAQ under the ticker symbol "KZIA."

Who are Kazia Therapeutics' major shareholders?

Kazia Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.60%), Truist Financial Corp (0.68%) and HighPoint Advisor Group LLC (0.53%).

Which institutional investors are buying Kazia Therapeutics stock?

KZIA stock was bought by a variety of institutional investors in the last quarter, including Truist Financial Corp, Morgan Stanley, and HighPoint Advisor Group LLC.

How do I buy shares of Kazia Therapeutics?

Shares of KZIA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kazia Therapeutics' stock price today?

One share of KZIA stock can currently be purchased for approximately $9.99.

How big of a company is Kazia Therapeutics?

Kazia Therapeutics has a market capitalization of $94.51 million and generates $710,000.00 in revenue each year. The company earns $-8,370,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis.

What is Kazia Therapeutics' official website?

The official website for Kazia Therapeutics is www.kaziatherapeutics.com.

How can I contact Kazia Therapeutics?

Kazia Therapeutics' mailing address is Three International Towers Level 24 300 Barangaroo Avenue, Sydney C3, 2000. The company can be reached via phone at 61-2-9472-4101 or via email at [email protected]

This page was last updated on 11/30/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.